Angelini inks $4.1B Catalyst takeover to fuel US expansion
Italy’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market.
ADVERTISEMENT
About Nick Paul Taylor
This author has not written his bio yet.
But we are proud to say that Nick Paul Taylor contributed 18 entries already.
Entries by Nick Paul Taylor
Scarlet raises £3.2 million to advance lab-grown red blood cell therapies
Scarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have comparable half-lives.
Cytospire raises £61M to take gamma-delta T-cell engager into the clinic
Cytospire Therapeutics has raised a £61 million (€71 million) Series A round, positioning the British biotech to advance pan-gamma-delta T-cell engagers (TCEs) into cancer clinical trials.
MoonLake’s sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s Bimzelx
Most inflammatory arthritis patients on MoonLake Immunotherapeutics’ sonelokimab met the response criteria, furthering the Swiss biotech’s attempt to challenge UCB for a blockbuster market.
Forbion and Sanofi drive $75M investment in COPD biotech Altesa
Forbion has led a $75 million investment in Altesa BioSciences, positioning the biotech to run a phase IIb trial in chronic obstructive pulmonary disease (COPD) patients in the second quarter.
Axol buys Newcells’ ophthalmology business to grow drug discovery portfolio
Axol Bioscience has acquired Newcells Biotech’s ophthalmology business to expand its portfolio of drug discovery and safety testing models.
Amgen wins European approval to challenge argenx and UCB for autoimmune market
The European Commission has approved Amgen’s Uplizna in generalized myasthenia gravis, moving the big biotech into a market served by argenx, Johnson & Johnson and UCB.
Zeon invests in Chemify to cut compound synthesis time using AI and robotics
Chemify has struck a deal with Zeon, securing investment from the company’s venture capital wing and signing up to make novel compounds and materials for its new partner.